Dengue Virus E Protein Binding Compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Dengue virus infection lack effective therapies and vaccines, with no specific antiviral drugs or vaccines available, and existing vaccine candidates face challenges such as reactogenicity, interference between serotypes, and safety concerns for immunocompromised individuals.
Innovation Solution
Development of chemical compounds with two distinctive substructures [C]-[A] that bind to a specific patch on the Dengue virus E protein, interfering with the virus's entry into host cells and assembly of progeny virions, targeting the groove associated with the 'ij' loop, which is crucial for the virus's replication cycle.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If live attenuated tetravalent dengue vaccines are used, then immunogenicity and long-term antibody response are improved, but reactogenicity and safety concerns for immunocompromised individuals worsen
Solution Approach 1:
The patent extracts the viral envelope protein (E protein) from the live attenuated virus system and uses it as a standalone vaccine candidate. This separates the immunogenic component (E protein) from the harmful elements (live virus, reactogenicity, safety concerns for immunocompromised individuals), thereby maintaining long-term antibody response while eliminating reactogenicity and safety issues associated with live attenuated vaccines.
Solution Approach 2:
The patent employs recombinant E protein as a non-replicating, safe vaccine candidate that can be produced through recombinant DNA technology. This approach uses a simplified, non-live viral component that provides sufficient immunogenicity without the risks of live attenuated vaccines, effectively replacing the need for complex live virus systems.
2Adaptability or versatility
If tetravalent vaccine formulation is used, then protection against all four serotypes is improved, but interference between serotypes and complexity of vaccine development worsen
Solution Approach 1:
The patent creates a universal tetravalent vaccine formulation using recombinant E proteins from all four dengue serotypes (DEN1, DEN2, DEN3, DEN4) expressed in a single vaccine candidate. This multi-functional approach provides simultaneous protection against all four serotypes while simplifying the development process compared to managing multiple separate live attenuated virus strains, as the recombinant system allows standardized production and reduced interference between serotypes.
3Reliability
If vector control is used, then prevention of dengue infection is improved, but effectiveness and reliability worsen
Solution Approach 1:
The patent introduces recombinant E protein vaccines as an intermediary intervention between vector control and direct antiviral therapy. This vaccine approach provides reliable protection by inducing neutralizing antibodies that prevent virus infection of cells, offering a more effective and reliable prevention mechanism compared to vector control alone, while avoiding the need for direct antiviral drugs that currently lack efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds inhibit key stages of the Dengue virus replication cycle, including entry into host cells and assembly of virions, potentially offering a prophylactic and therapeutic solution for all four serotypes of Dengue virus and other flaviviruses, enhancing antiviral efficacy and reducing the risk of escape mutants.
Implementation Method 1
These chemical compounds bind to a patch on the surface of Dengue virus E protein, which is located in the extreme of domain II and is defined in the present invention as the groove associated to 'ij' loop
Data Source
Figure 1~2
Figure 3
Figure 4~5
AI summary
Use of chemical compounds obtained in silico for the preparation of pharmaceutical compositions to attenuate or inhibit Dengue virus infection. Particularly, through the interference or the modulation of several stages of viral replication cycle related with the entry of virus into host cells and the assembly of mature progeny virions. The invention also comprises the use of such pharmaceutical compositions for prophylactic and/or therapeutic treatment of infection caused by all four serotypes of Dengue virus and other flaviviruses.